DNA
NYSEGinkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc. (DNA) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NYSE. In the last 30 days Quantisnow tracked 8 wire items for DNA, including 4 insider trades, 3 SEC filings and 1 earnings update. The most recent was published Nov 9, 2026.
DNA rankings
Financial highlights
Full financials- Revenue, TTM
- $130.75M
- Revenue growth
- -13.2%
- Net income, TTM
- -$251.03M
- Net margin
- -192.0%
- Free cash flow, TTM
- -$173.54M
- Cash
- $84.50M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks32+100%
2026-05-172026-11-08
Mix1790d
- Insider7(41%)
- Other5(29%)
- SEC Filings4(24%)
- Earnings1(6%)
Activity · 52 weeks7249 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECSEC Form 10-Q filed by Ginkgo Bioworks Holdings Inc.10-Q - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
- SECGinkgo Bioworks Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
- PRGinkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company NovoGinkgo provides an update on its third quarter financial results and the growth of its two prevailing offerings built on one autonomous lab platform: Autonomous Labs and Cloud Lab Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, "Ginkgo")) today announced its results for the third quarter of 2026 that ended September 30, 2026. The update, including a webcast slide presentation with additional details on the third quarter, as well as supplemental financial information, will be available at investors.ginkgobioworks.com. Third Quarter 2026 Financial Results Third quarter 2026 Revenue of $28 million compared to $29 million in the comparable prior year period, a decrease of 6%. Revenue increased
- SECSEC Form 8-K filed by Ginkgo Bioworks Holdings Inc.8-K - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
- INSIDEROfficer Coen Steven P. sold $7,770 worth of shares (766 units at $10.14) (SEC Form 4)4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
- INSIDEROfficer Shetty Reshma P. sold $417,608 worth of shares (41,172 units at $10.14) (SEC Form 4)4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
- INSIDERLarge owner Canton Barry sold $417,608 worth of shares (41,172 units at $10.14) (SEC Form 4)4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
- INSIDEROfficer Kelly Jason R sold $463,353 worth of shares (45,682 units at $10.14) (SEC Form 4)4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
- PRGinkgo Bioworks to Provide Autonomous Lab Access to NSF X-Labs Researchers, Contributing Cloud Lab Time and Protein Testing Services to $1.5 Billion Breakthrough Science ProgramGinkgo Bioworks (NYSE:DNA) today announced that it will provide in-kind access to its autonomous laboratory in Boston to support the National Science Foundation’s X-Labs program. Ginkgo’s support was announced today by Michael Kratsios, Director of the White House Office of Science and Technology Policy (OSTP), at the Science: A New Golden Age Summit in Washington, D.C. NSF X-Labs is a $1.5 billion, decade-long initiative to fund independent teams of researchers, engineers, and entrepreneurs pursuing breakthrough science through milestone-based awards. Through its contribution, Ginkgo will make cloud lab time on its autonomous lab available to NSF X-Labs teams, giving researchers remote a
- PRAraceli Biosciences and Ginkgo Bioworks Bring Cellular Imaging at Scale to Nebula's Lab-in-the-LoopThe Endeavor® adds the fastest high-content cellular data generation to Ginkgo's around-the-clock research PORTLAND, Ore. and BOSTON, Oct. 8, 2026 /PRNewswire/ -- Araceli Biosciences and Ginkgo Bioworks (NYSE:DNA) today announced the integration of Araceli's Endeavor® high-content imaging instrument into Nebula, Ginkgo's autonomous lab in Boston. The Endeavor, the world's fastest high-content imaging system, brings cellular imaging with real-time analysis to Nebula's existing technologies, giving researchers the large, curated datasets needed to train and validate drug discovery AI models. Nebula is built on Ginkgo's Reconfigurable Automation Carts (RACs). Each RAC is a modular unit that com
- INSIDEROfficer Coen Steven P. sold $36,045 worth of shares (2,403 units at $15.00) (SEC Form 4)4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
- PRGinkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability ConsortiumGinkgo generates antibody data at scale and trains models for drug manufacturability and developability. Apheris’ federated infrastructure enables participating pharmaceutical companies to use those models and further fine-tune them on their proprietary molecules or train new models using the consortium dataset. Ginkgo Datapoints, an offering of Ginkgo Bioworks (NYSE:DNA), and Apheris GmbH today announced that the Antibody Developability Consortium has kicked off with its founding members. The Consortium is a new industry collaboration designed to help pharmaceutical and biotech companies predict manufacturability and developability risks earlier by building the field’s largest standardiz
- INSIDERDirector Henry Christian O sold $35,405 worth of shares (5,000 units at $7.08), decreasing direct ownership by 21% to 19,310 units (SEC Form 4)4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
- PRGinkgo Datapoints Announces Partnership with TuneLab to Close the Gap between AI Models and Lab DataIntegration puts Ginkgo’s biological data generation services at the heart of the industry’s most prominent AI-driven drug discovery network Ginkgo Bioworks (NYSE:DNA) today announced that its Ginkgo Datapoints offering has entered into a new agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). TuneLab supports biotech innovation by enabling participating companies to access AI/ML drug discovery models trained on decades of Lilly's proprietary research data. Ginkgo Datapoints will provide discovery data generation services, including small molecule developability (ADME) and antibody developability testing, to TuneLab compa
- SECSEC Form 144 filed by Ginkgo Bioworks Holdings Inc.144 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
- PRGinkgo Bioworks Joins ARPA-H GIVE Program to Build Autonomous Manufacturing System for Individualized RNA MedicinesGinkgo plans to build the automation hardware and control software for ESCALATOR, a continuous-flow, autonomous manufacturing system designed to produce and quality-release RNA drug products at patient scale Ginkgo Bioworks (NYSE:DNA) today announced that it has been awarded a subcontract for up to $17.5M under the Advanced Research Projects Agency for Health’s (ARPA-H) Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program. Ginkgo will serve as a subcontractor to prime contractor Waterfall Scientific, Inc. on ESCALATOR (Engineering a Small-scale, Continuous-flow manufacturing Apparatus to Launch A Transformational Overhaul for RNA medicines), a multi-organization
- INSIDEROfficer Coen Steven P. converted options into 743 shares and sold $2,302 worth of shares (330 units at $6.98), increasing direct ownership by 0.80% to 51,851 units (SEC Form 4) (tax liability)4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
- ANALYSTGinkgo Bioworks downgraded by TD Cowen with a new price targetTD Cowen downgraded Ginkgo Bioworks from Buy to Hold and set a new price target of $9.00
- SECSEC Form 10-Q filed by Ginkgo Bioworks Holdings Inc.10-Q - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
- SECGinkgo Bioworks Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
- INSIDERSEC Form 4 filed by Large owner Canton Barry4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
- INSIDERSEC Form 4 filed by Officer Shetty Reshma P.4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
- INSIDERSEC Form 4 filed by Officer Kelly Jason R4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
- SECGinkgo Bioworks Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
- INSIDEROfficer Coen Steven P. converted options into 1,486 shares and sold $5,943 worth of shares (752 units at $7.90), increasing direct ownership by 1% to 51,438 units (SEC Form 4) (tax liability)4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
DNA FAQ
11 questionsWhat does Ginkgo Bioworks Holdings Inc. do?
Ginkgo Bioworks Holdings, Inc. develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is based in Boston, Massachusetts.What is the latest news on DNA?
In the last 30 days Quantisnow tracked 8 wire items for DNA: 4 insider trades, 3 SEC filings and 1 earnings update. The most recent was published on November 9, 2026.What is DNA revenue?
Ginkgo Bioworks Holdings Inc. (DNA) reported $130.75M of revenue for the twelve months ended Sep 30, 2026. That is down 13.2% from the year before. Revenue for fiscal 2025 was $170.16M.Is DNA profitable?
No. Ginkgo Bioworks Holdings Inc. reported a net loss of $251.03M for the twelve months ended Sep 30, 2026.How much cash and debt does DNA have?
Ginkgo Bioworks Holdings Inc. reported $84.50M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does DNA stock trade?
Ginkgo Bioworks Holdings Inc. (DNA) is listed on NYSE.What sector and industry is DNA in?
Ginkgo Bioworks Holdings Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Ginkgo Bioworks Holdings Inc. go public?
Ginkgo Bioworks Holdings Inc. (DNA) completed its IPO in 2021.What are analysts saying about DNA?
Across the last 8 analyst actions on Ginkgo Bioworks Holdings Inc., there were 0 upgrades and 7 downgrades. The most recent action was from TD Cowen: Hold with a $9.00 price target on 2026-08-07.What companies are similar to DNA?
Notable peers in the same industry include CDXS (Codexis Inc.), TWST (Twist Bioscience Corporation), ABSI (Absci Corporation). Compare DNA side-by-side with any of them on Quantisnow.How can I track DNA on Quantisnow?
Quantisnow aggregates Ginkgo Bioworks Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DNA to receive live email and push alerts on every new disclosure.